Chemotherapy-induced peripheral neurotoxicity: a critical analysis.
Susanna B. Park,David Goldstein,Arun V. Krishnan,Cindy S.-Y. Lin,Michael Friedlander,James T. Cassidy,Martin Koltzenburg,Matthew C. Kiernan +7 more
TLDR
This review will address the increasing importance and challenge of chemotherapy‐induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers.Abstract:
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of long-term toxicities and the impact on quality of life following treatment in cancer survivors. This review will address the increasing importance and challenge of chemotherapy-induced neurotoxicity, with a focus on neuropathy associated with the treatment of breast cancer, colorectal cancer, testicular cancer, and hematological cancers. An overview of the diagnosis, symptomatology, and pathophysiology of chemotherapy-induced peripheral neuropathy will be provided, with a critical analysis of assessment strategies, neuroprotective approaches, and potential treatments. The review will concentrate on neuropathy associated with taxanes, platinum compounds, vinca alkaloids, thalidomide, and bortezomib, providing clinical information specific to these chemotherapies. CA Cancer J Clin 2013;63:419-437. ©2013 American Cancer Society, Inc.read more
Citations
More filters
Journal ArticleDOI
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
James Wang,Kyle Udd,Aleksandra Vidisheva,Regina A. Swift,Tanya M. Spektor,Eric Bravin,Emad Ibrahim,Jonathan Treisman,Mohammed Masri,James R. Berenson +9 more
TL;DR: The results show that the severity of peripheral neuropathy is associated with lower vitamin D levels and provides the rationale for monitoring vitamin D for myeloma patients especially those receiving drugs associated with the development of peripheral Neuropathy.
Journal ArticleDOI
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy
Stefanie Kraff,Annemieke J.M. Nieuweboer,Ron H.J. Mathijssen,Florent Baty,Anne-Joy M. de Graan,Ron H.N. van Schaik,Ulrich Jaehde,Markus Joerger +7 more
TL;DR: This simulation study proposes a pharmacokinetically based dosing algorithm for weekly paclitaxel and shows potential improvement of the benefit/risk ratio by using empirical Bayesian models.
Journal ArticleDOI
One-dimensional poly(L-lysine)-block-poly(L-threonine) assemblies exhibit potent anticancer activity by enhancing membranolysis.
Yu Fon Chen,Ai Li Shiau,Sue Joan Chang,Nai Shin Fan,Chung Teng Wang,Chao Liang Wu,Jeng Shiung Jan +6 more
TL;DR: The fibril assemblies exhibited low hemolytic activity and selective cytotoxicity toward cancer cell, which is advantageous as compared to PLL and most antimicrobial/anticancerous peptides, which support the feasibility of using 1D fibrIL assemblies as potential apoptotic anticancer therapeutics.
Journal ArticleDOI
Vitamin E does not decrease the incidence of chemotherapy-induced peripheral neuropathy: a meta-analysis
TL;DR: Vitamin E administration dose not decrease the incidence of CIPN, and additional randomised controlled trials using large samples are needed to confirm the role of vitamin E supplementation.
Journal ArticleDOI
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Huang Ju Tu,Yi Jyun Lin,Min Wu Chao,Ting Yi Sung,Yi Wen Wu,Yi Ying Chen,Mei Hsiang Lin,Jing Ping Liou,Shiow Lin Pan,Chia-Ron Yang +9 more
TL;DR: The data highlighted that MPT0G211 in combination with chemotherapy drugs has significant anticancer activity, suggesting a novel strategy for the treatment of acute leukemia.
References
More filters
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Journal ArticleDOI
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André,Corrado Boni,Lamia Mounedji-Boudiaf,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Marta Zaninelli,Phillip Clingan,John Bridgewater,Isabelle Tabah-Fisch,Aimery de Gramont +11 more
TL;DR: Adding oxaliplatin to a regimen of fluorouracil and leucovorin improves the adjuvant treatment of colon cancer.
Journal ArticleDOI
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti,A. Dimitrios Colevas,Ann Setser,Valerie W. Rusch,David P. Jaques,Volker Budach,Corey J. Langer,Barbara A. Murphy,Richard Cumberlin,C. Norman Coleman,Philip Rubin +10 more
TL;DR: Recent progress in the evolution of adverse effects grading systems is updated and the development of CTCAE v3.0 is reviewed, which represents an international collaboration and consensus of the oncology research community.
Journal ArticleDOI
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values
Roman Rolke,Ralf Baron,Christoph Maier,Thomas R. Tölle,Rolf-Detlef Treede,Antje Beyer,Andreas Binder,Niels Birbaumer,Frank Birklein,I. C. Bötefür,S. Braune,Herta Flor,Volker Huge,R. Klug,G. B. Landwehrmeyer,Walter Magerl,Christian Maihöfner,C. Rolko,C. Schaub,Andrea Scherens,Till Sprenger,Michael Valet,B. Wasserka +22 more
TL;DR: Application of this standardized QST protocol in patients and human surrogate models will allow to infer underlying mechanisms from somatosensory phenotypes as well as judge plus or minus signs in patients.
Related Papers (5)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman,Christina Lacchetti,Robert H. Dworkin,Ellen M. Lavoie Smith,Jonathan Bleeker,Guido Cavaletti,Cynthia Chauhan,Patrick Gavin,Antoinette Lavino,Maryam B. Lustberg,Judith A. Paice,Bryan P. Schneider,Mary Lou Smith,Thomas J. Smith,Shelby A. Terstriep,Nina D. Wagner-Johnston,Kate Bak,Charles L. Loprinzi +17 more